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Abstract
Background: In colorectal cancer a distinct subgroup of tumours demonstrate the CpG island methylator phenotype (CIMP).
However, a consensus of how to score CIMP is not reached, and variation in definition may influence the reported CIMP
prevalence in tumours. Thus, we sought to compare currently suggested definitions and cut-offs for methylation markers
and how they influence CIMP classification in colon cancer.
Methods: Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA), with subsequent fragment
analysis, was used to investigate methylation of tumour samples. In total, 31 CpG sites, located in 8 different genes (RUNX3,
MLH1, NEUROG1, CDKN2A, IGF2, CRABP1, SOCS1 and CACNA1G) were investigated in 64 distinct colon cancers and 2 colon
cancer cell lines. The Ogino gene panel includes all 8 genes, in addition to the Weisenberger panel of which only 5 of the 8
genes included were investigated. In total, 18 alternative combinations of scoring of CIMP positivity on probe-, gene-, and
panel-level were analysed and compared.
Results: For 47 samples (71%), the CIMP status was constant and independent of criteria used for scoring; 34 samples were
constantly scored as CIMP negative, and 13 (20%) consistently scored as CIMP positive. Only four of 31 probes (13%)
investigated showed no difference in the numbers of positive samples using the different cut-offs. Within the panels a trend
was observed that increasing the gene-level stringency resulted in a larger difference in CIMP positive samples than
increasing the probe-level stringency. A significant difference between positive samples using ‘the most stringent’ as
compared to ‘the least stringent’ criteria (20% vs 46%, respectively; p,0.005) was demonstrated.
Conclusions: A statistical significant variation in the frequency of CIMP depending on the cut-offs and genes included in a
panel was found, with twice as many positives samples by least compared to most stringent definition used.
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Introduction
Cancer is a genetic disease caused by accumulation of molecular
changes and modifications on DNA that drives tumorigenesis [1].
Proper molecular characterisation of the cancer geno- and
phenotypes is important to reveal markers for early detection,
prognostication or prediction, as well as increase the understand-
ing of disease processes that may yield information for therapeutic
intervention. Colon cancer is a well investigated cancer model, for
which tumours are now separated into three phenotypical
subgroups, depending on the predominant type of genetic
aberrations: chromosomal instability (CIN) refers to changes at
the chromosome level (e.g. copy number changes); microsatellite
instability (MSI) refers to alterations in basepair-repeats (e.g. base
change in the dinucleotide repeat CA6), and; CpG island
methylator phenotype (CIMP) denotes an aberrant methylation
spectrum (e.g. hypo- or hyper methylated cytosines in the
promoter region), compared to normal cells [2,3].
CpG-island methylation testing has been proposed as a tool for
cancer detection, prognosis, and detection of residual disease in
both blood or other body fluids [4], and indicates that methylation
status is of clinical relevance [5–9]. Furthermore, methylation
specific assays are commercially available today to detect
colorectal cancer, either as testing for methylation of Vimentin
in faeces samples or testing for methylation of SEPT9 in blood
[6,10].
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In recent years, attention has been focused on the biology and
potential clinical importance of the CpG island methylator
phenotype (CIMP) in CRC [11,12]. While it is generally well
accepted that etiologically and clinically distinct subgroups exist
[13,14], a precise definition of CIMP remains to be established,
both methodologically and on a molecular level [15]. The
increasing use of high-throughput technologies also for methyla-
tion studies have shown great impact and suggested several panels,
e.g. to aid in the discrimination of colorectal tumour from epithelial
cells, differentiate between disease stages, prognostic groups, and
subgroups associated to other molecular features [16–18]. The
lack of consensus for determining the CIMP phenotype is partly
due to the fact that the cause of altered methylation pattern largely
remains unknown [13,19].
As a consequence, multiple gene panels, laboratory techniques,
and marker threshold values are currently in use, all of which may
result in differences in the reported prevalence of CIMP [20].
Since there is no universal standard or consensus on quantifying
the phenotype, establishing its true prevalence is a challenge and
hampers comparison between studies. Thus, the aims of this study
was to systematically test several criteria for defining CIMP in
colorectal cancer specimens, and investigate the difference in
CIMP frequency when altering score levels.
Methods
Human Material and Study Ethics
Cancer tissue was obtained from colon cancer patients
undergoing surgery at the Department of Gastrointestinal Surgery,
Stavanger University Hospital, Norway. Patients were recruited to
a prospective sentinel node trial, and all consented to study
participation prior to inclusion and tissue retrieval. The Western
Norway Regional Health Authority approved the use of human
participants after having written informed consent, approval
#197.04. All data were handled according to the Helsinki
declaration.
Tissue was obtained as previously described [21], and fresh-
frozen biopsies stored at -80 degree Celsius. A sample set of 64
stage II and III patients, and 2 colon cancer cell lines (Caco2 and
HT29), were arbitrarily selected for evaluation in the current
study.
DNA Isolation
Fresh frozen cancer tissue samples, from an equal number of
patients were included. Also, a reference sample of normal colonic
epithelium was obtained ensuring a considerable distance outside
the resection margin of the colon tumor. The DNA samples were
extracted using DNeasy Mini kit or AllPrep DNA&RNA Mini Kit
(Qiagen, Hilden, Germany).
Methylation-specific Multiplex Ligation-dependent Probe
Amplification (MS-MLPA) for CIMP Status
From all 64 DNA samples, 100 ng DNA were denatured in a
total volume of 5 ml Tris-EDTA buffer, and further performed as
recommended by the supplier (MRC-Holland, Amsterdam, the
Netherlands).
Methylation-specific multiplex ligation-dependent probe ampli-
fication (MS-MLPA) is a method for simultaneous detection of
methylation at several positions in one reaction [22,23]. In short, a
mixture of probe-mix (ME042-B1 CIMP, for more information on
the specific probes see Table S1) and buffer were added to the
denatured DNA, and probes were allowed to hybridize to the
DNA at 60 C for 16 hours. Each sample was divided in two tubes,
in which one half was ligated, and the other was ligated and
digested using the methylation-sensitive restriction enzyme HhaI.
Both samples were subsequently subjected to a PCR reaction using
a thermal cycler (GeneAmp 2700, Applied Biosystems, Foster
City, CA, USA), and fragment analysis performed on a capillary
sequencer (ABI 3130xl, Applied Biosystems, Foster City, CA,
USA). DNA from normal colonic mucosa was used as normal
reference. The output from the analysis, after inter- and intra-
sample normalization, is a percentage of methylation in the
sample.
Data Analysis of MLPA Data
The raw data from the fragment analysis were analysed using
the Coffalyser.NETTM Software, beta version, (MRC-Holland,
Amsterdam, the Netherlands). In short, the methylation of each
position in every sample relative to the reference was calculated
using Coffalyser.netTM software, with default settings.
All quality measures/parameters were within satisfactory range.
All samples were normalised against multiple runs of the reference
sample (inter sample normalisation), and furthermore, all probes
were adjusted to reference probes within each sample (intra
sample normalisation).
For methylation scoring of all probes within all samples, the
ratio of peak height of digested versus undigested sample were
calculated individually in Coffalyser, and the percentage of
methylation used for further analysis.
Definitions and cut-offs. In order to investigate differences
in CIMP frequency, which depended on the degree of methyla-
tion, different scoring parameters were tested.
Two panels of genes were investigated. The Ogino scoring
panel includes 8 genes (CACNA1G, IGF2, NEUROG1, RUNX3,
SOCS1, CDKN2A,MLH1 and CRABP1), whereas the Weisenberger
panel includes 5 of the above-mentioned genes (CACNA1G, IGF2,
NEUROG1, RUNX3 and SOCS1). For the Weisenberger panel
(called Weisenberger hereafter) a positive score for three or more
of the five genes is regarded CIMP positive, whereas for the Ogino
panel two different definitions were tested; CIMP positivity if 5 of
8 genes were positive (called Ogino 5/8), and CIMP positivity if 6
of 8 genes were positive (Ogino 6/8).
Furthermore, different cut-offs for scoring positive methylation
for each probe, as well as different definitions of the total
methylation status for a specific gene were investigated: All
positions/probes were scored using two different levels of
methylation ($20% or $30%) for defining a specific position/
probe as methylated. Three different cut-offs were tested for
defining methylation for each gene; either at least 33% (1/3) of
probes were methylated; at least 66% (2/3) were methylated, or;
having at least one or more methylated probes within the gene.
For each gene, several methylation sites were studied, ranging
from 3 to 6 sites per gene. The number of methylation sites for the
genes examined was as follows: 3 probes each for RUNX3,
CACNA1G and IGF2; 4 probes each for MLH1, CRABP1, SOCS1
and CDKN1A, and; 6 probes for NEUROG1.
For CIMP decision, the three panels were used in combination
with all the probe- and gene-wise cut-offs, Figure 1. This resulted
in a total of 18 alternative scoring definitions for CIMP.
Differences in positive samples were observed, and the statistical
significance evaluated.
The ‘most stringent criteria’ for scoring of CIMP were defined
as methylation of at least 30% on probe level, at least 66% positive
probes within a gene, and 6 out of 8 positive genes in the Ogino
panel. The ‘least stringent criteria’ were defined as 20%
methylation on probe level, one or more positive probes within
a gene, and 3 of 5 genes scored as positive in the Weisenberger
panel.
CIMP Frequency Using Different Scoring Criteria
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Statistical analysis. All statistical analyses were performed
by SPSS v21 (IBM Corp., Armonk, NY, US).
The number of positive samples resulting from each of the
different scoring criteria was compared using McNemars test on a
262 table. All tests were two-sided, and statistical significance
indicated for p-values ,0.05.
Results
Probe-wise Cut-off
For each probe, the relative methylation of the sample, as
compared to a normal reference, was given as a percentage. The
cut-off for scoring a probe as methylated was tested using both
20% and 30% methylation of sample vs reference, Figure 2. Both
cut-offs were tested for all probes in the assay. Overall, using 30%
as cut-off, the number of positive samples for the 31 different
probes tested, varied from 0 (0%) to 63 (95%), whereas using 20%
as cut-off, the variation was from 0 (0%) to 64 (97%). The mean
variation in scoring of positive samples between 20% and 30%
cut-offs were 3 (5%), varying from a minimum of 0 to a maximum
of 8 samples (0–12%). Four of 31 probes (13%), in two different
genes, showed no difference in the numbers of positive samples
using the two cut-offs (03-037010228 in MLH1, 16-011256544,
16-011256960 and 16-011257200 in SOCS1). The largest variation
was observed for probe 09-021965200 in CDKN2A, in which 8
patients (12%) were scored differently using the two different cut-
offs. Three probes (16-011256544, 16-011256960 and 16-
011257200 in SOCS1) did not have any positive samples using
either of the criteria, as the methylation percentage varied from 0
to 5%.
Gene-wise Cut-offs
The number of probes investigated for each gene varied from 3
to 6. Three different intra-gene settings were tested; one or more
positive probes, more than 33% positive probes or more than 66%
positive probes. All three settings were tested both for a probe-wise
cut-off of 20% and 30%.
This resulted in six scorings per gene, for which a mean of
44.8% of the samples were scored as positive over the 8 genes. The
mean percentage of positive samples across the genes, for each
score criteria, ranged from 34.3% to 57.0%, using the most
stringent (30% probe cut-off, 66% positive probes per gene), and
least stringent criteria (20% probe cut-off, $1 positive probe per
gene), respectively, Table 1.
SOCS1 had the lowest number of positive samples, with a mean
score of positive samples of 5.8%, ranging from 0 to 18.2%,
whereas the mean score of positive samples for IGF2 was 96.0%
for the 6 alternative criteria, ranging from 92.4 to 97.0%, Table 1/
Figure 3.
CDKN2A showed largest variation in positive samples using the
6 alternative criteria. The number of positive samples varied by 39
samples, ranging from 5 to 44, using the most stringent and least
stringent criteria, respectively. On the contrary, RUNX3 and IGF2
showed the least variation; in both cases only 3 patients were
scored differently over the 6 different criteria. For RUNX3 24
patients were scored as positive using the most stringent criteria,
compared to 27 patients with the least stringent criteria. For IGF2
the number of positive samples was 61 and 64, using the most and
least stringent criteria, respectively.
CIMP Frequencies
The outcome, in terms of number of positive samples using each
of the three panels, including the different combinations of probe-
wise and gene-wise scorings, are presented in Table 2/Figure 4.
The most stringent criteria, using a probe cut-off of 30%, and
demanding that 2 out of three (.66%) of the probes within a
certain gene must be positive, in addition to using the Ogino 6/8
panel, returned 13 (20%) CIMP-positive samples. On the
contrary, using a probe cut-off of 20%, requiring at least one or
more positive probe within a gene, and the Weisenberger panel (3
out of 5 positive genes), returned 30 (45%) CIMP-positive samples.
When using the least stringent criteria on probe- (20%) and
gene- ($1 positive genes) level, 24 samples (36%) were scored as
positive using Ogino 6/8-panel, 29 positive (44%) using Ogino 5/
8-panel and 30 positive (46%) using Weisenberger panel. These
probe- and gene level criteria resulted in the largest variation
between the panels, resulting in 6 patients (9.1%) being scored
differently. For 47 patient samples (71%), the CIMP status was
constant and independent of criteria used for scoring; 34 samples
were constantly scored as CIMP negative, and 13 scored as CIMP
positive.
A significant difference between positive samples using the most
stringent (20%) as compared to the least stringent (46%) criteria
was demonstrated, p,0.005. When comparing the least stringent
criteria on both probe-level (20%) and gene-level ($1 positive
probe) between the three panels, only the Ogino 6/8 compared to
the Weisenberger panel showed a significant difference (p = 0.031).
On the contrary, the most stringent criteria on probe- and gene
level did not return significant differences between the panels.
Testing for differences within each of the panels, showed that
increasing the stringency on gene-level from the least stringent
($1) to the most stringent (66%), keeping the probe level constant,
resulted in significant different number of positive samples. On the
other hand, keeping the gene level constant, while changing the
probe level, did result in significant different positive samples for
the $1 criteria, within the Weisenberger panel only.
Figure 1. Illustration of the three levels of scoring, the panels and genes, and number of probes investigated in the presented
study.
doi:10.1371/journal.pone.0086657.g001
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Discussion
Independent of methodology used, criteria for scoring of CIMP
would need to be defined at three levels; which genes should be
tested, how many methylation sites should be affected for the gene
to be transcriptionally inactivated, and to which extent a
methylation site must be methylated to affect the transcription
status of the gene.
This study found a significant difference in the CIMP frequency
in colon cancer using MS-MLPA methodology, when comparing
different criteria used for defining methylated samples. Although a
high percentage of samples (71%) were consistently scored (of
which 13 were CIMP positive) with no change according to
criteria used, the remainder were influenced by a change in
scoring criteria set. Notably, only four of 31 probes (13%)
investigated showed no difference in the numbers of positive
samples using the different cut-offs. The largest variation was
observed for one of the probes in the CDKN2A gene. For the 8
genes investigated, RUNX3 and IGF2 were most consistent with
little variation among samples, while considerable variation was
noted for CDKN2A, in accordance to results reported by Ogino
et al. [20]. The criteria used resulted in significantly different
number of positive samples when used for the two suggested panels
to define CIMP status in the literature, namely the Ogino- and the
Weisenberger panels [20,24].
The findings pose several important implications. For one, it
demonstrates variation between the frequency of CIMP depending
on the cut-offs and genes investigated in a panel. This should be
noted when investigators use CIMP as part of the classification
suggested for colorectal cancer. Second, it demonstrates variability
in methylation within and across genes. This may either be related
to true differences within genes and the investigated probes, or
related to technique used for identification. If the former is true,
the reason to why certain sites are (more consistently) methylated
while others are not should be investigated, as it may form new
knowledge about carcinogenesis and how methylation may
contribute to cancer development. Further, it may be that genes
and probes (such as RUNX3 and IGF2) should be used together
with other or similarly consistently methylated genes in panels to
form decision on CIMP status, in order to avoid over- or
underestimation of CIMP positive or negative samples.
The presented study was conducted in order to evaluate the
relevance of using alternative scoring criteria for CIMP, by using
methylation specific multiplex ligation-dependent probe amplifi-
Figure 2. Scoring of methylated probes using a cutoff of 20% (red) and 30% (blue). The axis to the left shows the number of positive
samples, and the axis on the right shows the percentage of positive samples.
doi:10.1371/journal.pone.0086657.g002
Table 1. Methylation status for each gene based on different criteria.
RUNX3 MLH1 NEUROG1 CDKN2A IGF2 CRABP1 SOCS1 CACNA1G
Criteria
Mean (%)
P: 30% G: 66% 24 (36) 14 (21) 42 (64) 5 (8) 61 (92) 19 (29) 0 (0) 16 (24) 34,3
P: 30% G: 33% 25 (38) 19 (29) 53 (80) 19 (29) 64 (97) 21 (32) 0 (0) 23 (35) 42,4
P: 30% G: $1 25 (38) 33 (50) 57 (86) 35 (53) 64 (97) 23 (35) 11 (17) 23 (35) 51,3
P: 20% G: 66% 26 (39) 15 (23) 48 (73) 7 (11) 63 (95) 20 (30) 0 (0) 22 (33) 38,1
P: 20% G: 33% 27 (41) 20 (30) 57 (86) 25 (38) 64 (97) 23 (35) 0 (0) 26 (39) 45,8
P: 20% G: $1 27 (41) 35 (53) 60 (91) 44 (67) 64 (97) 33 (50) 12 (18) 26 (39) 57,0
Overall Mean (%) 38,9 34,3 80,1 34,1 96,0 35,1 5,8 34,3
Number, and percentages (in parentheses), of positive samples for each gene using different scoring criteria. The criteria mean column indicates the mean percentage
of positive samples using the specific criteria, while the overall mean row indicates the percentage of positive samples per gene. P = probe-level cut-off, G = Gene-level
cut-off.
doi:10.1371/journal.pone.0086657.t001
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cation (MS-MLPA). In the published literature there are several
studies evaluating gene panels and CpG positions to be used for
CIMP scoring, but the underlying cut-offs for the specific position
and gene are poorly discussed [11,20,24].
In this study, the difference in number of positive samples using
the most stringent as compared to the least stringent criteria was
statistically significant, and indicates that the chosen cut-offs used
for scoring of CIMP status is important. Furthermore, statistical
analyses also showed that combinations of all three levels of
scoring alternatives gave statistically different number of positive
samples, implying that all three levels should be carefully
evaluated. However, within all three panels, changing the gene
level criteria had a larger impact on the number of samples scored
as positive than changing the probe level criteria. Even if several
different methods could be used to detect the CIMP phenotype, all
these methods will have to consider the scoring criteria underlying
the CIMP definition. Independent of methodology used, one will
have to consider which CpG sites to study and define a cut-off for
methylation of the specific CpG site, define how many CpG sites
within the gene which will need to be methylated to define the
gene as methylated, and finally, which genes, and how many of
them will need to be methylated to eventually score the sample as
methylated.
Differences in CIMP scoring between gene panels have been
evaluated [20], and found to be quite small (,3.2%), even
between panels using different genes. Also, a comparison of cut-off
for the Ogino panel (5 of 8 and 6 of 8) was compared, and 3% of
the samples showed different scoring (18% and 15%, respectively)
[20].
Figure 3. The number (left vertical axis) and percentage (right vertical axis) of samples scored as positive for each gene using all
combinations of probe- and gene-wise cut-offs.
doi:10.1371/journal.pone.0086657.g003
Figure 4. Number of positive patient samples using comparing alternative scoring probe-wise, gene-wise and panel-wise.
doi:10.1371/journal.pone.0086657.g004
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In general, independent of criteria and method used for scoring
of CIMP, the degree of methylation measured for a given position
would depend on the homogeneity of the cells, and infiltration of
normal cells in the sample studied.
Also, the choice of normal reference sample for each study
should be carefully evaluated, as the methylation of a sample is
relative to the chosen reference. In this study we used a sample
from normal epithelium from a colon cancer patient. In theory,
this sample could harbour some epigenetic features influencing the
results of the methylation pattern in the cancer samples. However,
this will affect all samples equally, and is therefore of minimal
relevance with regards to evaluating scoring criteria. Given the
opportunity, the best option would have been to test normal
mucosa tissue from the patient where the tumour tested originates
from alongside the tumour itself. Given the limited material we
had available, our best option was to use the before-mentioned
control and thus present the data accordingly.
Most reports of CIMP status have used bisulphite treatment of
the DNA prior to the chosen method of interrogation of the
methylation pattern. This manipulation of the DNA converts
unmethylated cytosines to uracils, while the methylated are left
unconverted. There are several protocols for bisulphite treatment,
differing in the bisulphite concentration used and incubation/
conversion time, and add another level of complexity to the
conclusive CIMP status. In the study presented herein, no DNA
treatment has been done prior to the MLPA method, thus limiting
the source of errors.
Further, the fact that methylation of gene are fluctuating
naturally in order to regulate gene expression, and that the nature
of the epigenome, contrary to the genome, is to be in constant
transformation, is another aspect complicating a clear definition of
CIMP [25]. To circumvent this challenge one would have to rely
on material that have been collected at the same time interval and
stage in the patients treatment, as such avoiding possible time-
lapse discrepancies.
Conclusions
In conclusion, this study illuminates how different scoring
criteria result in statistically significant different number of CIMP
positive samples. The definition of CIMP in colorectal cancer is
not yet agreed upon, neither on a qualitative level (which CpG
islands/genes that should be tested), on a quantitative level (how
many positions needs to be methylated), nor on a technical level
(what methodology is to be used). However, irrespective of the
methodology used one would have to decide on cut-offs for
positive scoring, which should be carefully evaluated, as the
resulting CIMP frequency will be significantly influenced by this
decision. Further research into this important area is warranted to
improve clinical translation of the role of CIMP in cancer.
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